An international survey on liver metastases radiotherapy

Figures & data

Table I. Respondent demographics.

Regional/country of practice (n = 69)
Europe	22 (32%)
Australia/New Zealand	13 (19%)
United States of America	14 (20%)
Canada	17 (25%)
Other	3 (4%)
Primary oncology membership (n = 69)
ASTRO	17 (25%)
ESTRO	18 (26%)
CARO	16 (23%)
TROG/ RANZCR	13 (19%)
OTHER	5 (7%)
Year of completion of training (n = 69)
≤ 1985	7 (10%)
1986–1990	10 (14%)
1991–1995	13 (19%)
1996–2000	18 (26%)
2001–2005	13 (19%)
2006–2012	8 (12%)
Type of practice (n = 69) *Multiple response options
Directly government funded	21 (26%)
Private practice	22 (28%)
Academic/University	37 (46%)
Type of primary practice setting (n = 69)
Hospital based	61 (88%)
Free-standing	8 (12%)
Type of reimbursement received (n = 69)
Fee-for-service	14 (20%)
Salary	41 (59%)
Both	11 (16%)
Other	3 (4%)
Years of treating liver cancer (n = 69)
0–4	25 (36%)
5–9	16 (23%)
10–14	8 (12%)
15–19	11 (16%)
20 or more	9 (13)

Figure 1. Contraindications to liver radiation.